48 results
6-K
EX-99.1
SPRC
SciSparc Ltd
8 Mar 24
SciSparc Issued Canadian Patent for Opioids Reduction Use in Pain Management Technology
9:00am
to 2030. The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected
F-1
SPRC
SciSparc Ltd
27 Feb 24
Registration statement (foreign)
4:15pm
in the presence of PEA. Collectively, the results indicated that treatment with SCI-160 significantly alleviates both chronic and acute pain. Based on the positive … , prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely
6-K
EX-99.1
SPRC
SciSparc Ltd
31 Oct 23
SciSparc Granted Patent from the Australian Patent Office for its Reduction of Opioids Use in Pain Management Technology
8:15am
to 2030. The increasing rate of regulatory approvals and the launch of new opioid medicines to treat patients with chronic pain are the factors expected … market growth in chronic pain treatment, and that the Company is able to offer effective and safe treatments. Historical results of scientific research
6-K
EX-99.1
SPRC
SciSparc Ltd
18 Oct 23
Report of Foreign Private Issuer
6:54am
In 2031 ** Pain and Inflammation The global chronic pain treatment market was estimated at US$ 81.36 billion in 2021 and is expected to surpass … - analysis/alzheimers - therapeutics - market ***** https://www.growthplusreports.com/report/chronic - pain - treatment - market/ 8030
2023
6-K
EX-99.1
d3bbk1bis3
12 Jun 23
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
7:02am
6-K
EX-99.1
b29irj0yk zi
2 Aug 22
SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome
4:00pm
6-K
EX-99.1
e6g2r 6sqqfwch
29 Jun 22
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
8:36am
6-K
EX-99.1
q6f xxvptn1
1 Jun 22
SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems
4:11pm
6-K
EX-99.1
qgmqxil4bg
26 May 22
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
8:33am
6-K
EX-99.1
wa7nkpt
22 Feb 22
Report of Foreign Private Issuer
9:05am
6-K
EX-99.2
hw6ajq4z2ococoy
16 Aug 21
Interim Consolidated Financial Statements
12:00am
6-K
EX-99.1
zvx9 ya7h3m8khq8153
4 Aug 21
SciSparc Announces Completion of Corporate Rebranding and Launch of New Website
4:44pm
6-K
EX-99.1
vne7yb
28 Jul 21
SciSparc Announces Updates Regarding its Phase IIb Study in Tourette Syndrome
4:00pm
6-K
EX-99.1
yh2f3v13nu
24 Feb 21
SciSparc Corporate Presentation February 2021
9:27am
6-K
EX-99.1
ngi45 b351yloqszz6
11 Feb 21
SciSparc Announces Rebranding and Business Updates
10:01am
6-K
EX-99.1
r4ty 9f13felh3cb
10 Feb 21
SciSparc Engages Procaps for Development and Production of CannAmide™ and its SCI-110 Product Candidate
8:33am